particle morphology hints impurity rejection
play

particle morphology hints impurity rejection capability during API - PowerPoint PPT Presentation

Revealing shapes particle morphology hints impurity rejection capability during API crystallization Jochen Schll Technobis webinar on 24 SEP 2020 WAG XLab MSD Werthenstein BioPharma in Schachen Lucerne Medicine is for the people.


  1. Revealing shapes – particle morphology hints impurity rejection capability during API crystallization Jochen Schöll Technobis webinar on 24 SEP 2020 WAG XLab

  2. MSD Werthenstein BioPharma in Schachen Lucerne

  3. “ Medicine is for the people. It is not for the profits.” George W. Merck (1950) 3

  4. Main tasks in pharma crystallization Process: • Solvent system • Temperature • Addition rates • etc … 4

  5. Typical development challenge: limited amount of API and 3 ways to make most out of it: Data-rich Miniaturization Parallelization experimentation 5

  6. Approaches in our lab Data-rich Miniaturization Parallelization experimentation 6

  7. Crystallization issues during 1 st GMP delivery (1.5 kg API) Solvent switch crystallization • Quantiles [ µ m] (EtOAC → Toluene) successfully x 10 40.2 rejected impurities but failed x 50 78.0 controlling solid form x 90 152.6 Additional recrystallization from • MeOH/Water was needed to Unmilled API control the crystal form Final micronization step via • Quantiles [ µ m] spiral jet milling yielded 1.5 kg x 10 1.4 API x 50 4.1 x 90 8.1 Jet-milled API 7

  8. Solvent (pre-)selection with HT data Average [mg/ml] Average [mg/ml] Average [mg/ml] Solvent Selection Solvent Selection Solvent Selection High-throughput solubility • Acetone 90.14 50:50 EtOH:H2O 0.46 2:1 DMF:H2O 8.24 50.41 0.06 1.10 MeCN 25:75 EtOH:H2O 1:1 DMF:H2O data provides a first set of EtOH 8:1 EtOH:H2O 1:1 DMF:MeOH 9.87 10.20 > 100 H2O 0.00 2:1 EtOH:H2O 3.33 2:1 DMAc:H2O 9.06 potential solvent systems: Toluene 3.87 95:5 IPA:H2O 9.45 1:1 DMAc:H2O 0.91 THF >100 90:10 IPA:H2O 10.27 2:1 NMP:H2O 16.93 0.00 9.01 1.38 Heptane 80:20 IPA:H2O 1:1 NMP:H2O ➢ Good solvents IPAc 50:50 IPA:H2O 0.12 1:1 Toluene:MeOH 52.46 22.46 DMF >100 25:75 IPA:H2O 0.15 1:1 Toluene:MeCN 73.57 NMP >100 2:1 IPA:H2O 4.75 1:1 Toluene:EtOH 31.25 MeOH 17.95 8:1 IPA:H2O 10.61 1:1 Toluene:IPA 22.83 2-methylTHF 60.72 95:5 THF:H2O >100 1:1 IPAc:MeOH 37.36 ➢ Good antisolvents DCM 90:10 THF:H2O 1:1 MeCN:EtOH 49.77 >100 54.20 >100 >100 1.40 DMAc 80:20 THF:H2O 1:1 2-methylTHF:Heptane DMSO >100 50:50 THF:H2O 0.69 1:1 THF:MTBE 32.77 EtOAc 49.83 25:75 THF:H2O 0.09 1:1 Toluene:MTBE 5.50 ➢ Risky systems IPA 5.90 2:1 THF:H2O 36.07 1:1 IPAc:MTBE 13.46 MTBE 3.58 8:1 THF:H2O >100 1:1 IPA:MTBE 7.86 2-butanol 4.59 90:10 Acetone:H2O >100 2:1 Acetone:Water 60.48 MEtOAc 80:20 Acetone:H2O 1:1 Acetone:Water 76.10 0.11 15.85 n-propanol 6.85 50:50 Acetone:H2O 0.07 1:1 EtOH:Heptane 8.32 Hexane 0.00 25:75 Acetone:H2O 0.07 1:1 THF:Heptane 2.85 90:10 MeCN:H2O 68.43 2:1 Acetone:H2O 0.08 2:1 THF:Heptane 0.30 80:20 MeCN:H2O 45.79 8:1 Acetone:H2O 49.13 9:1 THF:Heptane 81.30 50:50 MeCN:H2O 95:5 MeOH:H2O 1:1 IPA:Heptane 0.84 10.17 3.63 0.08 8.75 0.37 25:75 MeCN:H2O 90:10 MeOH:H2O 1:1 Toluene:Heptane 95:5 EtOH:H2O 50:50 MeOH:H2O 2:1 IPAc:Heptane 11.79 0.17 7.81 90:10 EtOH:H2O 11.59 2:1 MeOH:H2O 0.98 1:1 IPAc:Heptane 3.01 80:20 EtOH:H2O 7.50 8:1 MeOH:H2O 8.74 1:1 MTBE:Heptane 0.22 1:1 DCM:Heptane 0.00 8

  9. API with two known forms Both, polar and apolar solvent • systems successfully generated the desired Form 2 at lab scale Seeded process with • Form 2 supersaturation control expected to yield desired form EtOAc/Heptane MeCN/Water Form 1 9

  10. First results at 300 mg scale Particle morphoplogy changes in different solvents – potential for different impurity rejection? • Apolar solvent systems Polar solvent system EtOAc/Heptane IPAc/Heptane MeCN/Water 10

  11. Crystallization and impurities in the literature Dichloromethane Ethanol 11

  12. Development work for 2 nd GMP delivery Apolar solvent systems Polar solvent system EtOAc/Heptane 2-MeTHF/Heptane MeCN/Water EtOAc/Heptane 2MeTHF/Heptane MeCN/Water API purity 99.9% LCAP 99.9% LCAP <99.0% LCAP Form control X ✓ ✓ Color rejection insufficient insufficient insufficient 12

  13. Data-rich experiment at 3 g scale – EtOAc/Heptane Yield ≈ 96 % Vol. prod. ≈ 62 g/L Cycle time ≈ 18 h Form impurity (rods) Temperature 13

  14. Crust formation Hot reactor walls induce Cool reactor walls avoid “creeping”, “creeping”: but still on probes & stirrer: 14

  15. Activated carbon treatment & rex in 2MeTHF/Heptane Crude API Pure API Crystallization + Activated carbon 15

  16. Successful 2 nd GMP delivery (27 kg API) Improved chemistry reduced RM • Quantiles [ µ m] cost by 40x x 10 1.4 New API crystallization process • x 50 4.1 Eliminates the need for recrystallization • x 90 8.1 due to improved impurity rejection Ensures robust API form control (lower • seed mass was compensated by extended seed age) Rejects color using AC • Delivered 27 kg API with a higher • crystallization yield of +13% Jet-milled API 16

  17. Potential to eliminate jet milling? Unseeded high-shear • reverse additions have been performed in MeCN/Water and EtOAc/Heptane API crystallization process Polar and apolar systems • yielded mix of forms Ongoing work with • seeded reverse addition 17

  18. Summary • Different particle morphologies can indicate impurity rejection differences (lower aspect ratio correlates with higher purity) • Combination of miniaturization and data-rich experiments allowed for an optimized process design regarding impurity rejection, form control, de-coloring, and process yield • Further work on bottom-up process with form control ongoing Thank you! 18

  19. Q&A Acknowledgements - Erica Schwalm - Eric Ashley - Eric Sirota - Siwei Zhang - Yonggang Chen

Recommend


More recommend